CervoMed price target raised to $20 from $15 at Roth MKM

Roth MKM raised the firm’s price target on CervoMed (CRVO) to $20 from $15 and keeps a Buy rating on the shares. The firm is positive on the company’s DLB – dementia with Lewy bodies – program, given the positive Phase 2b data de-risking neflamapimod’s therapeutic utility in early-stage DLB patients who are currently devoid of approved therapy, the analyst tells investors in a research note. Pending FDA regulatory alignment, CervoMed could begin the registration-enabling Phase 3 study in mid-2026, the firm added.